title: [An update on gout: diagnostic approach, treatment and comorbidity].
abstract: Muskuloskeletal ultrasound and dual-energy-CT (DECT) findings are increasingly relevant for the establishment of the diagnosis of gout, and are therefore incorporated into the novel ACR / EULAR classification criteria. Canakinumab, a monoclonal antibody directed against interleukin-1β (IL-1β) has been approved in 2013 for the treatment of acute gout and for prophylaxis of flares. In patients demonstrating an inadequate response upon treatment with allopurinol or febuxostat, combination therapy with lesinurad might reduce uric acid levels to the target of < 6 mg / dl (< 5 mg / dl in tophaceous gout). Rapid lowering of uric acid levels and effective tophi reduction can be achieved with pegloticase, which can be utilized in selected patients presenting contraindications to xanthine oxidase inhibitors and uricosuric drugs. This article summarizes current scientific aspects of diagnosis, treatment and comorbidities of gout in the context of clinical relevance.
authors: Magnus
authors: M
authors: Diller
authors: Martin
authors: M
authors: Fleck
mesh_terms: D015897:Comorbidity; D006073:Gout / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000628:therapy; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans
chemical_list: D006074:Gout Suppressants